Company intelligence / Profile preview

Combangio, Inc.

Ownership: Public · KALA
Development stage: Other

Overview

KPI-012 showed positive safety and efficacy signals in a Phase 1b trial where seven out of eight patients treated twice daily improved; six achieved complete corneal healing within weeks. The treatment was well tolerated with no safety issues reported. A $15 million grant from California Institute for Regenerative Medicine supports ongoing Phase 2b CHASE trial evaluating two doses versus vehicle control with topline data expected Q1 2024[1][2][3][4][6].

Therapeutic areas: Ophthalmology
Modalities: Regenerative biotherapies based on mesenchymal stem cell secretomes (MSC-S)Biologics-based investigational therapiesSecretome therapy derived from bone marrow MSCs
Industry: Biotech

Partnerships

California Institute for Regenerative Medicine funding partnership ($15M grant)

Beyond the preview

Go deeper on Combangio, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Combangio, Inc..